

# Influence of atrial fibrillation on oxygen uptake and exercise tolerance in cardiovascular patients; close association with heart rate response

Nami Takano<sup>a,b,\*</sup>, Eisuke Amiya<sup>a,\*\*</sup>, Gaku Oguri<sup>a</sup>, Atsuko Nakayama<sup>a</sup>, Masanobu Taya<sup>a</sup>, Toshiaki Nakajima<sup>c</sup>, Hiroyuki Morita<sup>a</sup>, Issei Komuro<sup>a</sup>

<sup>a</sup> Department of Cardiovascular Medicine, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, Japan

<sup>b</sup> Center for Health Check-up and Preventive Medicine, Kanto Central Hospital, 6-25-1 Kamiyoga, Setagaya-ku, Tokyo, Japan

<sup>c</sup> Heart Center, Dokkyo Medical University Hospital, 880 Kitakobayashi, Mibu, Tochigi 321-0293, Japan

## ARTICLE INFO

### Article history:

Received 6 November 2018

Received in revised form 7 December 2018

Accepted 22 December 2018

Available online 8 January 2019

### Keywords:

Atrial fibrillation

Oxygen uptake

O<sub>2</sub> pulse

Heart rate response

Hemodynamic trend

## ABSTRACT

To investigate the effect of atrial fibrillation (AF) on the oxygen uptake and exercise tolerance, we evaluated cardiopulmonary exercise test (CPET) data in AF patients and heart rate-matched controls with sinus rhythm (cSR) who received ambulatory cardiac rehabilitation. We compared CPET data between AF ( $N = 27$ ) and cSR patients ( $N = 106$ ) who had similar HRs at rest and the peak points. Oxygen uptake ( $\text{VO}_2$ )/kg and relative O<sub>2</sub> pulse (ml/bpm/kg) at rest and the anaerobic threshold (AT) level was not different between AF and cSR patients, but these parameters above the AT level were significantly lower in AF than in cSR patients. Concisely the parallel increase of relative O<sub>2</sub> pulse during exercise was blunted above the respiratory compensation level (Rc) in the AF group. In addition, the HR change during exercise was inversely correlated with the increase of the O<sub>2</sub> pulse above the AT level and this inverse correlation was more prominent in AF patients than in cSR patients. In conclusion, the value of  $\text{VO}_2$  was significantly lower above the AT level in AF patients. The trend of O<sub>2</sub> pulse above the AT level was strongly associated with the detrimental response of HR increase and the response was markedly exaggerated in the AF patients.

© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## 1. Introduction

Atrial fibrillation (AF) is a major cardiac rhythm disturbance that is frequently encountered in clinical practice. Even though AF is common in patients with underlying cardiac diseases, it also occurs in those without and increases in prevalence with advanced age [1]. AF may be associated with the worsening of heart failure or the occurrence of thrombotic events, which significantly affect patients' prognoses [2]. However, it may also have detrimental effects on patients' daily lives because of reduced exercise tolerance [3]. Exertional dyspnea is a frequently observed complaint in patients with AF, with patients reporting a significant impairment in their quality of life (QoL) [4].

Rate control therapy, including both heart rate control and anticoagulant therapy, is unable to improve AF-derived exertional dyspnea. On the contrary, the development of new therapeutic strategies against AF, including catheter ablation, has clearly improved the symptomatology for each patient [5].

Exercise tolerance is a useful parameter that corresponds with and greatly influences QoL in patients. In the PIAF trial, it was believed that exercise tolerance was better with rhythm control than rate control; however, a clinically meaningful difference was not observed [6]. The STAF pilot study also showed no significant difference in exertional dyspnea between the two treatment strategies [7]. Furthermore, it was reportedly difficult to accurately determine the differences in exertional symptoms between sinus rhythm patients and AF patients [6,8].

An improvement in physical activity should be regarded as being imperative to the personalization of AF therapy, as symptoms could be determined by the balance between a patient's exercise capacity and daily physical activity. For appropriate personalization of therapy for AF patients, further investigation into exercise physiology in AF is warranted [9,10]. In particular, the effects of heart rate (HR) on exercise capacity, which, in AF patients are complicated, in part due to an exaggerated HR increase during exercise, itself may have a significant impact on exercise tolerance [11,12]. Cardiopulmonary exercise testing (CPET) is the standard criterion for assessing exercise capacity and has proven beneficial for evaluating the exercise capacity in patients with various extents of cardiac dysfunction.

The primary aim of our study was to examine the influences of cardiac hemodynamics, such as oxygen uptake by AF, independent of the effect of HR increase during exercise.

\* Correspondence to: N. Takano, Department of Cardiovascular Medicine, the University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, Japan.

\*\* Corresponding author.

E-mail addresses: [namikubota-circ@umin.ac.jp](mailto:namikubota-circ@umin.ac.jp) (N. Takano), [amiyae-ty@umin.ac.jp](mailto:amiyae-ty@umin.ac.jp) (E. Amiya).

## 2. Method

### 2.1. Study population

We obtained data on 934 cases of CPET from 422 patients undergoing ambulatory cardiac rehabilitation for heart failure or ischemic heart disease between 2009 and 2015 at the University of Tokyo Hospital (Fig. 1). Exclusion criteria were a history of heart transplant; severe illnesses other than heart disease, such as malignant tumors; or the presence of any clinical comorbidity that might interfere with exercise performance. Patients were also excluded if they (a) were < 45 years of age or > 80 years of age, (b) were unable to achieve an adequate pedal rotation speed or had a maximum respiratory exchange ratio < 1.05 during CPET, (c) performed CPET by the minority protocol which is different from the main protocol mentioned below, (d) had an HR at rest of > 110 bpm, or (e) showed the presence of moderate valvular disease, which was thought to be the cause of the patient's symptoms. If the patients performed CPET more than once, the highest value of peak oxygen consumption ( $\text{VO}_2/\text{kg}$ ) was selected for this study.

The AF group ( $N = 27$ ) comprised those subjects with an AF rhythm at the time of CPET, whereas the subjects with a sinus rhythm (SR) were defined as the SR group ( $N = 228$ ). From the SR group, the HR-matched controls whose heart rates at rest and peak exercise were matched with those of the AF group were selected ( $N = 106$ ) and defined as the cSR group. CPET parameters in the AF group were compared with those in the cSR group.


Informed consent was obtained from each patient, and the study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki and was reviewed and approved by the University of Tokyo Institutional Review Board (2650).

### 2.2. Cardiopulmonary exercise testing

Symptom-limited CPET was performed on an electromagnetically braked upright cycle ergometer (Corival, Load, Holland) with a metabolic gas analyzer (AE-300S; Minato Medical Science, Osaka, Japan). After 4 min of rest on the cycle ergometer, exercise commenced at 20 watt for a 4 min-warm up; then, the work rate was increased by 1 watt every 6 s. During CPET, blood pressure was measured by an automatic, indirect cuff manometer (FB-300; Fukuda Denshi, Tokyo, Japan) every min. HR and electrocardiography (ECG) were monitored using an exercise electrocardiogram (ML-9000; Fukuda Denshi, Tokyo, Japan). The criteria for discontinuation of CPET were (i) if pedal rotations were delayed; (ii) if the patient reached maximum symptom-limited performance determined by a Borg score of  $\geq 17$ ; (iii) when 85% of age-predicated maximal HR was achieved; or (iv) if there was evidence of ST-T changes in ECG or if any cardiac event, such as arrhythmia or chest pain, occurred. Expired gases were continuously measured in all subjects on a breath-by-breath basis. The anaerobic threshold (AT) was determined by gas-exchange criteria as the point of nonlinear increase in ventilation equivalents for oxygen.

### 2.3. CPET parameters

The values of  $\text{VO}_2$  and HR at rest (Rest; average of 4 min of rest on the cycle ergometer), warm up (Wu; average of 3–4 min after exercise commenced), AT, the respiratory compensation point (Rc), and the exercise peak (Peak) were all measured and recorded during CPET. Peak  $\text{VO}_2$  was defined as the average value obtained during the last 20 s of incremental exercise or the average of 20 s around the highest value obtained during the CPET.  $\text{O}_2$  pulse, which was calculated by



**Fig. 1.** Enrollment criteria and flow chart of the study. CR, cardiac rehabilitation; CPET, cardiopulmonary exercise test; AF, atrial fibrillation; SR, sinus rhythm; cSR, heart rate-matched controls with sinus rhythm; RER, respiratory exchange ratio; HR, heart rate;  $\text{VO}_2$ , oxygen uptake; N, number of patients.

**Table 1**

Baseline characteristics of patients in the AF and cSR groups.

N, number of patients; AF, atrial fibrillation; HR, heart rate; SR, sinus rhythm; BMI, body mass index; CAD, coronary artery disease; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; RAS, renin–angiotensin system; ARB, angiotensin II receptor blockers; ACE, angiotensin-converting enzyme. Data are presented as the mean  $\pm$  SD or number (%) of patients.

| Variable                 | Patients with AF (N = 27) | HR-matched controls with SR (N = 106) | P value  |
|--------------------------|---------------------------|---------------------------------------|----------|
| Gender (women/men)       | (6/21)                    | (26/80)                               | 0.80     |
| Age (years)              | 68.4 $\pm$ 8.0            | 65.2 $\pm$ 8.4                        | 0.07     |
| weight (kg)              | 67.7 $\pm$ 12.0           | 64.3 $\pm$ 11.3                       | 0.17     |
| BMI (kg/m <sup>2</sup> ) | 25.0 $\pm$ 3.3            | 23.6 $\pm$ 3.1                        | 0.04*    |
| Diagnosis                |                           |                                       |          |
| Hypertension             | 24 (88.9)                 | 81 (76.4)                             | 0.16     |
| CAD (%)                  | 15 (55.6)                 | 77 (72.6)                             | 0.08     |
| PCI                      | 10                        | 65                                    |          |
| CABG                     | 3                         | 13                                    |          |
| Cardiomyopathy           | 4 (14.9)                  | 5 (4.7)                               | 0.15     |
| Valvular heart disease   | 9 (33.3)                  | 8 (7.5)                               | 0.001**  |
| Diabetes mellitus (%)    | 12 (44.4)                 | 47 (44.3)                             | 0.99     |
| Medication (%)           |                           |                                       |          |
| Calcium channel blockers | 10 (37.0)                 | 47 (44.3)                             | 0.64     |
| Non-dihydropyridine      | 4 (14.8)                  | 4 (3.8)                               | 0.03*    |
| RAS blockers             | 21 (77.8)                 | 71 (67.0)                             | 0.28     |
| ARB                      | 13 (48.1)                 | 44 (41.5)                             |          |
| ACE inhibitor            | 8 (29.6)                  | 30 (28.3)                             |          |
| Beta blockers            | 17 (63.0)                 | 51 (48.1)                             | 0.17     |
| Statins                  | 16 (59.3)                 | 74 (69.8)                             | 0.42     |
| Diuretics                | 12 (44.4)                 | 19 (17.9)                             | 0.004**  |
| Digoxine                 | 12 (44.4)                 | 0 (0)                                 | <0.001** |

\*\*  $P < 0.001$ .\*  $P < 0.05$ .

dividing  $\text{VO}_2$  by HR, was obtained at Rest, Wu, AT, Rc, and Peak point during CPET.

The minute ventilation/carbon dioxide production relation slope ( $\text{VE}/\text{VCO}_2$  slope), the slope of the increase in ventilation to the increase in  $\text{CO}_2$  output, was calculated during incremental exercise using least squares linear regression.

Percent-predicted  $\text{VO}_2/\text{kg}$  at AT and Peak were calculated according to published age and sex-normalized values for healthy Japanese of the same age and sex [13].

#### 2.4. Examinations

Standard echocardiographic imaging was performed for the evaluation of left ventricular (LV) ejection fraction (EF), diameters of the left ventricle and left atrium (LA), and assessment of right ventricular systolic pressure (RVSP). The presence or absence of valvular heart disease was also evaluated. The brain natriuretic peptide (BNP) and hemoglobin levels were measured within 1 month before or after CPET.

#### 2.5. Statistical analysis

Data are presented as the mean  $\pm$  standard deviation. All calculations were made using the JMP statistical software package v.11.0 (SAS institute Inc., Tokyo, Japan) and the PASW Statistics 18 (SPSS Inc., Chicago, IL, USA).

The prevalence of any underlying disease, the indices obtained from echocardiography, and the indices obtained from CPET were compared between the AF and cSR groups using unpaired *t*-test, Mann–Whitney *U* test, or Fisher's exact test, where appropriate. Categorical variables are expressed as absolute numbers with percentages. Comparisons of the trends in  $\text{VO}_2$  and HR during exercise between the AF and cSR groups were achieved using two-way ANOVA with repeated measurements. One-way repeated ANOVA was used to compare the values of  $\text{VO}_2$  and HR during exercise between each timing in each group. Comparisons of the variables between the AF and cSR groups were performed using

Student's *t*-test with Bonferroni correction. Comparisons of the variables between adjacent time points in each group were performed using Student's *t*-test with Bonferroni correction. A *P* value  $< 0.05$  was considered statistically significant. Two correlations were compared by Z-score, calculated by Fisher *r*-to-*z* transformation.

### 3. Results

#### 3.1. Baseline characteristics


The patients in the AF group included 21 men (77.8%) with a mean age of  $68.4 \pm 8.0$  years (Table 1). The cSR group included 80 men (75.5%) with a mean age of  $65.2 \pm 8.4$  years. Although the patients in the AF group were older on average compared with the cSR group, the difference was not statistically significant. Regarding the cardiovascular background, the proportion of patients with ischemic heart disease was high in the cSR group, whereas the proportion of patients with valvular disease was high in the AF group. Calcium channel blockers, renin–angiotensin system blockers, beta blockers, and statins were prescribed

**Table 2**

Cardiopulmonary exercise testing, laboratory data, and echocardiography parameters of patients in the AF and cSR groups.

N, number of patients; AF, atrial fibrillation; HR, heart rate; SR, sinus rhythm; Rest, average of 4 min of rest; AT, anaerobic threshold; Peak, exercise peak;  $\text{VO}_2$ , oxygen uptake; %AT; percent-predicted  $\text{VO}_2/\text{kg}$  at AT; %Peak; percent-predicted  $\text{VO}_2/\text{kg}$  at Peak;  $\text{VE}/\text{VCO}_2$  slope; the minute ventilation/carbon dioxide production relation slope; Hb, hemoglobin; BNP, brain natriuretic peptide; LVEF, left ventricular ejection fraction; LVDd, left ventricular end-diastolic diameter; LVDs, left ventricular end-systolic diameter; LAD, left atrial dimension; RVSP, right ventricular systolic pressure. Data are presented as the mean  $\pm$  SD.

| Variable                                             | Patients with AF (N = 27) | HR-matched controls with SR (N = 106) | P value       |
|------------------------------------------------------|---------------------------|---------------------------------------|---------------|
| CPET parameters                                      |                           |                                       |               |
| Peak watts                                           | 87.9 $\pm$ 14.9           | 93.7 $\pm$ 22.9                       | 0.22          |
| Heart rate (bpm)                                     |                           |                                       |               |
| at Rest                                              | 78.4 $\pm$ 13.4           | 78.5 $\pm$ 10.2                       | 0.98          |
| at AT                                                | 109 $\pm$ 17.5            | 106.6 $\pm$ 11.6                      | 0.40          |
| at Peak                                              | 139.1 $\pm$ 19.8          | 134 $\pm$ 13.7                        | 0.12          |
| Systolic/diastolic blood pressure (mmHg)             |                           |                                       |               |
| at Rest                                              | 116 $\pm$ 26/72 $\pm$ 14  | 123 $\pm$ 21/73 $\pm$ 12              | 0.13/0.56     |
| at AT                                                | 144 $\pm$ 21/79 $\pm$ 12  | 161 $\pm$ 24/80 $\pm$ 13              | 0.001**/0.61  |
| at Peak                                              | 165 $\pm$ 27/83 $\pm$ 13  | 191 $\pm$ 28/86 $\pm$ 15              | <0.001**/0.43 |
| $\text{VO}_2$ (ml/min)                               |                           |                                       |               |
| at Rest                                              | 222 $\pm$ 41.7            | 223 $\pm$ 44.8                        | 0.91          |
| at AT                                                | 751.4 $\pm$ 122.8         | 770 $\pm$ 175.5                       | 0.61          |
| at Peak                                              | 1056 $\pm$ 190.1          | 1134.2 $\pm$ 287.6                    | 0.18          |
| $\text{VO}_2/\text{kg}$ (ml/kg/min)                  |                           |                                       |               |
| at Rest                                              | 3.3 $\pm$ 0.5             | 3.5 $\pm$ 0.6                         | 0.12          |
| at AT                                                | 11.2 $\pm$ 1.3            | 12.1 $\pm$ 2.4                        | 0.06          |
| at Peak                                              | 15.7 $\pm$ 2              | 17.7 $\pm$ 3.3                        | 0.004**       |
| $\text{O}_2$ pulse (ml/bpm)                          |                           |                                       |               |
| at Rest                                              | 2.9 $\pm$ 0.75            | 2.87 $\pm$ 0.6                        | 0.82          |
| at AT                                                | 7.02 $\pm$ 1.42           | 7.34 $\pm$ 1.68                       | 0.36          |
| at Peak                                              | 7.76 $\pm$ 1.92           | 8.53 $\pm$ 2.2                        | 0.10          |
| Relative $\text{O}_2$ pulse (ml/bpm/kg $\times$ 100) |                           |                                       |               |
| at Rest                                              | 4.4 $\pm$ 1.2             | 4.5 $\pm$ 0.9                         | 0.45          |
| at AT                                                | 10.5 $\pm$ 2.2            | 11.3 $\pm$ 2.2                        | 0.09          |
| at Peak                                              | 11.6 $\pm$ 2.5            | 13.2 $\pm$ 2.3                        | 0.001**       |
| %AT (%)                                              | 69.2 $\pm$ 8.8            | 76 $\pm$ 12.4                         | 0.06          |
| %Peak (%)                                            | 67.0 $\pm$ 9.5            | 73.7 $\pm$ 13.8                       | 0.02*         |
| $\text{VE}/\text{VCO}_2$ slope                       | 30.6 $\pm$ 5.1            | 29.4 $\pm$ 5.6                        | 0.33          |
| Laboratory data and cardiac indices                  |                           |                                       |               |
| Hb (g/dl)                                            | 13.7 $\pm$ 1              | 13.3 $\pm$ 1.6                        | 0.30          |
| BNP (pg/ml)                                          | 144.3 $\pm$ 88.1          | 55.1 $\pm$ 57.5                       | <0.001**      |
| LVEF (%)                                             | 59.8 $\pm$ 10.2           | 60.8 $\pm$ 12.4                       | 0.68          |
| LVDd (mm)                                            | 49.0 $\pm$ 5.5            | 48.5 $\pm$ 6.1                        | 0.68          |
| LVDs (mm)                                            | 33.0 $\pm$ 7              | 32.3 $\pm$ 7.8                        | 0.7           |
| LAD (mm)                                             | 49.5 $\pm$ 7.2            | 37.0 $\pm$ 7.1                        | <0.001**      |
| RVSP (mmHg)                                          | 30.3 $\pm$ 5.9            | 23.5 $\pm$ 11.1                       | 0.004**       |



**Fig. 2.** Changes in the HR,  $VO_2/kg$ , and relative  $O_2$  pulse in the AF and cSR groups during exercise. J, statistically significant change from the previous time point of exercise in the cSR group; S, statistically significant change from the previous time point of exercise in the AF group; \*\*, statistically significant difference between the AF and cSR groups; AF, atrial fibrillation; cSR, heart rate-matched controls with sinus rhythm; HR, heart rate;  $VO_2$ , oxygen uptake; Rest, average of 4 min of rest; Wu, average of 3–4 min after exercise commenced; AT, anaerobic threshold; RC, respiratory compensation point; Peak, exercise peak.

to patients in the AF group as well as to patients in the cSR group. However, non-dihydropyridine calcium channel blocker, diuretics and digoxin were used frequently in the AF group (Table 1). Amiodarone was prescribed to one patient in cSR group.

### 3.2. Differences in $VO_2/kg$ between AF and cSR groups at each point of exercise

The HR at Rest, Wu, AT, Rc, and at Peak were not significantly different between the AF and cSR groups (Table 2 and Fig. 2). The systolic blood pressure at AT and Peak in the AF group were significantly lower than those in the cSR group. Peak watts in the AF group were lower than that in the cSR group, but the difference was not significant. In terms of  $VO_2/kg$ , the values of  $VO_2/kg$  increased during exercise in both groups; however, there was a significantly different trend between AF and cSR. In addition,  $VO_2/kg$  at Rest, Wu and AT were not significantly different between the AF and cSR groups, whereas  $VO_2/kg$  at Peak was significantly impaired in the AF group. Similarly, there was a significant difference between the AF and cSR groups in the relative  $O_2$  pulse, which is exemplified by  $VO_2$  per HR standardized by body weight.


According to the time course of  $VO_2/kg$  and relative  $O_2$  pulse during exercise, the values of  $VO_2/kg$  were increased during exercise in both groups. In contrast, relative  $O_2$  pulse was increased in accordance with

the exercise time in the cSR group, whereas relative  $O_2$  pulse at Rc and Peak in the AF group had no difference. Therefore, the slope of relative  $O_2$  pulse along the increase of exercise was blunted for the AF group compared with that of the cSR group.

Other than CPET parameters, the BNP level was significantly higher in the AF group than in the cSR group (Table 2). Left atrial dimension (LAD) and RVSP were significantly higher in the AF group than in the cSR group. There were no differences in LVEF between the AF and cSR groups.

### 3.3. Blunted increase in relative $O_2$ pulse in the AF group

We continued our investigation by examining the trend of the  $O_2$  pulse in the AF group (Fig. 3, Table 3).  $O_2$  pulse trend ratio was calculated by  $O_2$  pulse at Peak/ $O_2$  pulse at AT, and AF patients were divided into two groups according to  $O_2$  pulse trend ratio (median = 1.1). High  $O_2$  pulse trend (high- $O_2p$  trend) had the  $O_2$  pulse trend ratio > 1.1, whereas low  $O_2$  pulse trend (low- $O_2p$  trend) had the  $O_2$  pulse trend ratio < 1.1. In the low- $O_2p$  trend group, the HR at Rest was comparatively low compared with the high- $O_2p$  trend group. HR change from Rest to Peak (HR reserve) was significantly higher in the low- $O_2p$  trend group as compared with that of high- $O_2p$  trend group. In contrast, the  $O_2$  pulse was comparatively increased below the Rc level in the low- $O_2p$  trend



**Fig. 3.** Changes in the HR,  $VO_2/kg$ , and relative  $O_2$  pulse in AF patients after divided into two groups according to  $O_2$  pulse trend ratio. J, statistically significant change from the previous time point of exercise in the high  $O_2$  pulse trend group; S, statistically significant change from the previous time point of exercise in the low  $O_2$  pulse trend group; The horizontal axis shows each point during CPET. AF, atrial fibrillation; cSR, heart rate-matched controls with sinus rhythm; HR, heart rate;  $VO_2$ , oxygen uptake; Rest, average of 4 min of rest; Wu, average of 3–4 min after exercise commenced; AT, anaerobic threshold; RC, respiratory compensation point; Peak, exercise peak.

**Table 3**

Characteristics of AF patients after they were divided into two groups according to O<sub>2</sub> pulse trend ratio calculated by O<sub>2</sub> pulse at Peak/O<sub>2</sub> pulse at AT (median = 1.1).

N, number of patients; AF, atrial fibrillation; BMI, body mass index; CAD, coronary artery disease; RAS, renin–angiotensin system; Rest, average of 4 min of rest; AT, anaerobic threshold; Peak, exercise peak; VO<sub>2</sub>, oxygen uptake; %AT; percent-predicted VO<sub>2</sub>/kg at AT; %Peak; percent-predicted VO<sub>2</sub>/kg at Peak; VE/VCO<sub>2</sub> slope; the minute ventilation/carbon dioxide production relation slope; HRR, heart rate reserve; %HRR, percentage of heart rate reserve; Hb, hemoglobin; BNP, brain natriuretic peptide; LVEF, left ventricular ejection fraction; LVDD, left ventricular end-diastolic diameter; LVDs, left ventricular end-systolic diameter; LAD, left atrial dimension; RVSP, right ventricular systolic pressure. Data are presented as the mean ± SD or number of patients.

| Variable                                              | Low O <sub>2</sub> pulse trend group (N = 13) | High O <sub>2</sub> pulse trend group (N = 14) | P value   |
|-------------------------------------------------------|-----------------------------------------------|------------------------------------------------|-----------|
| <b>Clinical characteristics</b>                       |                                               |                                                |           |
| Gender (women/men)                                    | (4/9)                                         | (2/12)                                         | 0.57      |
| Age (years)                                           | 69.4 ± 6.2                                    | 67.6 ± 9.5                                     | 0.57      |
| Weight (kg)                                           | 66.1 ± 13.6                                   | 69.2 ± 10.5                                    | 0.52      |
| BMI (kg/m <sup>2</sup> )                              | 24.9 ± 3.9                                    | 25.1 ± 2.9                                     | 0.87      |
| <b>Diagnosis</b>                                      |                                               |                                                |           |
| Hypertension                                          | 12                                            | 12                                             | 0.56      |
| CAD                                                   | 7                                             | 8                                              | 0.83      |
| Valvular heart disease                                | 5                                             | 4                                              | 0.89      |
| Diabetes mellitus                                     | 5                                             | 7                                              | 0.83      |
| <b>Medications</b>                                    |                                               |                                                |           |
| Calcium channel blockers                              | 7                                             | 3                                              | 0.24      |
| Non-dihydropyridine                                   | 4                                             | 2                                              | 0.30      |
| RAS blockers                                          | 11                                            | 10                                             | 0.72      |
| Beta blockers                                         | 6                                             | 11                                             | 0.18      |
| Statins                                               | 7                                             | 9                                              | 0.87      |
| Diuretics                                             | 7                                             | 5                                              | 0.58      |
| Digoxin                                               | 5                                             | 7                                              | 0.83      |
| <b>CPET parameters</b>                                |                                               |                                                |           |
| Peak watts                                            | 86.1 ± 16.3                                   | 89.6 ± 13.8                                    | 0.54      |
| <b>Heart rate (bpm)</b>                               |                                               |                                                |           |
| at Rest                                               | 72.7 ± 13.5                                   | 83.7 ± 11.4                                    | 0.03*     |
| at AT                                                 | 106.5 ± 15.8                                  | 111.4 ± 19.3                                   | 0.48      |
| at Peak                                               | 145.9 ± 21.4                                  | 132.9 ± 16.6                                   | 0.09      |
| <b>Systolic/diastolic blood pressure (mmHg)</b>       |                                               |                                                |           |
| at Rest                                               | 119 ± 18/73 ± 13                              | 114 ± 33/71 ± 15                               | 0.62/0.79 |
| at AT                                                 | 151 ± 21/79 ± 12                              | 137 ± 19/78 ± 12                               | 0.07/0.94 |
| at Peak                                               | 175 ± 29/85 ± 14                              | 155 ± 22/82 ± 12                               | 0.05/0.51 |
| <b>VO<sub>2</sub> (ml/min)</b>                        |                                               |                                                |           |
| at Rest                                               | 217.2 ± 42.6                                  | 226.5 ± 41.9                                   | 0.57      |
| at AT                                                 | 769.5 ± 155.8                                 | 734.6 ± 84.3                                   | 0.47      |
| at Peak                                               | 1037.3 ± 223.6                                | 1073.4 ± 159.5                                 | 0.63      |
| <b>VO<sub>2</sub>/kg (ml/kg/min)</b>                  |                                               |                                                |           |
| at Rest                                               | 3.3 ± 0.6                                     | 3.3 ± 0.3                                      | 0.75      |
| at AT                                                 | 11.7 ± 1.3                                    | 10.7 ± 1.2                                     | 0.053     |
| at Peak                                               | 15.8 ± 1.9                                    | 15.6 ± 2.2                                     | 0.86      |
| <b>O<sub>2</sub> pulse (ml/bpm)</b>                   |                                               |                                                |           |
| at Rest                                               | 3.1 ± 0.9                                     | 2.7 ± 0.5                                      | 0.23      |
| at AT                                                 | 7.3 ± 1.5                                     | 6.8 ± 1.3                                      | 0.34      |
| at Peak                                               | 7.2 ± 1.8                                     | 8.3 ± 2                                        | 0.16      |
| <b>Relative O<sub>2</sub> pulse (ml/bpm/kg × 100)</b> |                                               |                                                |           |
| at Rest                                               | 4.8 ± 1.6                                     | 4.0 ± 0.5                                      | 0.07      |
| at AT                                                 | 11.3 ± 2.4                                    | 9.9 ± 1.9                                      | 0.10      |
| at Peak                                               | 11.1 ± 2.5                                    | 12.0 ± 2.6                                     | 0.36      |
| %AT (%)                                               | 71.3 ± 8                                      | 65.5 ± 7.4                                     | 0.06      |
| %Peak (%)                                             | 67.9 ± 9.3                                    | 66.2 ± 9.88                                    | 0.65      |
| VE/VCO <sub>2</sub> slope                             | 30.3 ± 5.5                                    | 30.8 ± 4.9                                     | 0.80      |
| HR reserve (bpm)                                      | 73.2 ± 18.9                                   | 49.1 ± 12.3                                    | 0.001**   |
| %HRR (%)                                              | 96.4 ± 29.3                                   | 74.0 ± 22.9                                    | 0.04*     |
| <b>Laboratory data and cardiac indices</b>            |                                               |                                                |           |
| Hb (g/dl)                                             | 13.2 ± 1.1                                    | 14.1 ± 0.8                                     | 0.02*     |
| BNP (pg/ml)                                           | 142.3 ± 99.4                                  | 146.2 ± 79.1                                   | 0.91      |
| LVEF (%)                                              | 58.9 ± 8.9                                    | 60.5 ± 11.4                                    | 0.70      |
| LVDD (mm)                                             | 49.1 ± 4.9                                    | 48.9 ± 6.2                                     | 0.93      |
| LVDs (mm)                                             | 32.8 ± 5.9                                    | 33.1 ± 8                                       | 0.91      |
| LAD (mm)                                              | 48.5 ± 5.9                                    | 50.4 ± 8.3                                     | 0.51      |
| RVSP (mmHg)                                           | 30.0 ± 6.5                                    | 30.5 ± 5.3                                     | 0.82      |

group, whereas, above the Rc level, there was no increase in the O<sub>2</sub> pulse in the low-O<sub>2</sub>p trend group. In the high-O<sub>2</sub>p trend group, the increase in the O<sub>2</sub> pulse was somewhat low below the Rc level compared with that of the low-O<sub>2</sub>p trend group, whereas the O<sub>2</sub> pulse at peak in the high-O<sub>2</sub>p trend group exceeded that in the low-O<sub>2</sub>p trend group. From these results, blunted increase in relative O<sub>2</sub> pulse in the AF group was associated with HR increase during exercise.

We compared the contributions of the HR change (from Rest to Peak/from Rest to AT/from AT to Peak) during exercise on the value of O<sub>2</sub> pulse trend ratio (= O<sub>2</sub> pulse at Peak/O<sub>2</sub> pulse at AT) between the AF and cSR groups (Fig. 4). There was a significant inverse-correlation between the HR change and the O<sub>2</sub> pulse trend ratio in AF patients, whereas the association was comparatively weak in the cSR group. These inverse correlations between O<sub>2</sub> pulse trend ratio and the HR change from Rest to Peak as well as those from AT to Peak were significantly different by Z-score analysis between AF and cSR groups.


#### 4. Discussion

The exercise capacity of AF patients is greatly affected by the HR response. In the present study, we identified HR-matched controls with SR who had a similar HR trend to AF patients during exercise and, we demonstrated that the value of VO<sub>2</sub>/kg is significantly lower in AF patients above the AT level. This study ultimately suggests that exercise impairment in the setting of AF is developed above the exercise level of the AT point after standardization of HR [14,15]. The results of this study show that adverse effects on the hemodynamics due to AF become apparent with a load exceeding the AT level. Regarding the hemodynamic derangement of AF, rhythm irregularity and loss of atrial contribution to LV filling impair cardiac output in AF patients [3]. Exercise capacities in AF patients have been shown to be impaired by multiple pathways, such as endothelial dysfunction or neurohumoral factors [16,17]. In addition, hemodynamic effects derived from AF change according to the exercise level.

Our results were similar to those of Elshazly et al. [18], in which the value of VO<sub>2</sub> below the AT point was similar between AF and SR patients. HRs at baseline and peak were higher in AF patients in Elshazly's study as compared with ours. In our study, the hemodynamic trend in AF was verified even after the deleting the effect derived from exaggerated HR response in the AF group. Atrial emptying is mainly performed by conduit flow, which is induced by LV longitudinal contraction in light exercise [19]. This is closely associated with LV properties rather than intrinsic LA function. These findings suggest that the impact of left atrial abnormalities in AF patients is comparatively smaller than the effect derived from LV factors. In contrast, during moderate exercise atrial emptying is induced mainly by atrial contraction and is therefore greatly affected by the presence of AF [19]. These mechanistic insights correspond well to the findings that exercise derangement in AF patients was demonstrated above the level of moderate exercise in the present study.

However, there are some contradictory findings regarding the relationship between exercise load and the contribution of atrial function. Linde-Edelstam et al. demonstrated that the importance of atrial contraction to ventricular filling diminishes in accordance with increasing blood flow velocity as the exercise work load increases [20]. Furthermore, left atrial pressure determines the contribution of atrial contraction to LV filling, and the elevation of pulmonary capillary wedge pressure was reported to diminish the power of atrial contraction on the cardiac output [17]. These studies suggest that multiple factors affect the contribution of atrial-derived factors on the cardiac output. Further investigations should be conducted to better understand the mechanism underlying decreased O<sub>2</sub> pulse in AF patients.

Another interesting aspect of this manuscript is the close association between the HR response and increase in the O<sub>2</sub> pulse above the AT level. The inverse association between HR change, which is a marker of chronotropy, and the increase in the O<sub>2</sub> pulse above the AT level is



**Fig. 4.** Correlative relationships between the O<sub>2</sub> pulse trend ratio (O<sub>2</sub> pulse at Peak/O<sub>2</sub> pulse at AT) and HR change from Rest to Peak, Rest to AT and AT to Peak.

strikingly enhanced in AF patients. The HR change during exercise could predict the trend of the O<sub>2</sub> pulse at the submaximal stage. In addition, there were two different groups with different trends in the O<sub>2</sub> pulse in AF patients; one wherein VO<sub>2</sub> is maintained above the AT level by increasing HR and one wherein VO<sub>2</sub> is maintained by increasing the stroke volume. The blunted increase in the O<sub>2</sub> pulse above the AT level corresponded to the enhanced response of chronotropy, maintaining the value of VO<sub>2</sub>/kg. However, there were no differences in laboratory data, echocardiographic parameters, and medication profiles.

Several studies have demonstrated the association between HR or HR response and exercise capacity [21,22]. The enhanced HR response in AF patients has been demonstrated in previous studies [14,23] and has been reported to be due to an increased sympathetic drive triggered to maintain cardiac output. However, increasing HR does not always improve exercise tolerance or symptoms in AF patients [24]. Indeed, the degree of exaggerated chronotropic response evoked an unfavorable effect on cardiac output above the moderate intensity of exercise and the unfavorable effect was more enhanced in AF patients. In this study, there was no significant

difference in HR trend between AF and cSR patients, which could demonstrate the different association of HR response and the change of cardiac output between AF and cSR patients in more sophisticated manner. However, the relationship between exercise capacity and HR response is more complicated in AF patients. The determinant factors of chronotropy in AF patients had been warranted more concisely [25,26]. Another possible determining factor of chronotropy in AF is atrial function, such as atrial appendage emptying velocity or atrial contractile function. In order to verify it, the more detailed evaluation of atrial function should be performed.

The findings of the current study suggested that, aerobic exercise is generally performed as a main protocol of cardiac rehabilitation, in which the change of O<sub>2</sub> pulse during exercise had similar behavior between patients with sinus rhythm and AF. However, the exercise capacity is significantly impaired above the level of AT and the change of HR reflected the burden of exercise in a more exaggerated manner in patients with AF than patients with sinus rhythm.

## 5. Study limitations

There are several limitations in the present study, which includes a small study population without healthy controls. In addition, the patient population was limited to those receiving cardiac rehabilitation, which could evoke referral bias because patients referred for cardiac rehabilitation are not representative of the general community population. In selecting cSR patients, there was some possibility that they were different from SR patients and the difference of chronotropic competency may be a candidate to segregate the cSR group from a general SR group, which, however, is above the scope of this study. The elucidation of basic characteristics of these classifications is also warranted. Because the disease severity in our patients was mild and the study population included only Japanese patients, the results should be carefully interpreted when applied to different populations. The voluntary participation of the study patients in ambulatory cardiac rehabilitation may introduce some bias in the present study. In addition, the study design was limited regarding the evaluation of the effect of medications. Among them, the medication of beta blockers should be carefully considered because it might significantly affect the behavior of HR. However, there were no significant differences in HR trend, VO<sub>2</sub>/kg trend during exercise in AF patients in this study.

## 6. Conclusion

Hemodynamic derangement during exercise derived from AF was developed above the moderate intensity exercise such as AT and the VO<sub>2</sub> was significantly lower in AF patients than HR-matched control above AT. Additionally, the HR change during exercise was inversely correlated with the increase of O<sub>2</sub> pulse. Especially the inverse correlation between the increase of O<sub>2</sub> pulse and HR change above AT was significantly enhanced in AF patients. It may be beneficial for AF patients to be reevaluated for exercise tolerance so that the quality and usefulness of rhythm control can be better determined.

## Acknowledgments

We would like to thank Haruhito Takano, Yumiko Yamamoto, Hidemi Akejima, Hitomi Koshi, and Kazuya Fukumura for their assistance with the ambulatory cardiac rehabilitation and exercise studies. The authors would like to thank Enago ([www.enago.jp](http://www.enago.jp)) for the English language review.

## Grants

This work was supported by The Ministry of Education, Culture, Sports, Science and Technology of Japan through Grant-in-aid 17K09488 (to Amiya E).

## Conflict of interest statement

The authors report no relationships that could be construed as a conflict of interest.

## References

- [1] A. Arowolaju 2nd, R.F. Gillum, A new decline in hospitalization with atrial fibrillation among the elderly, *Am. J. Med.* 126 (2013) 455–457.
- [2] M. Rienstra, V.E. Hagens, D.J. Van Veldhuisen, H.A. Bosker, J.G. Tijssen, O. Kamp, J. Bouma, N.J. Veeger, H.J. Crijns, I.C. Van Gelder, RATE Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group, Clinical characteristics of persistent lone atrial fibrillation in the RACE study, *Am. J. Cardiol.* 94 (2004) 1486–1490.
- [3] K. Pardaens, J. Van Cleemput, J. Vanhaecke, R.H. Fagard, Atrial fibrillation is associated with a lower exercise capacity in male chronic heart failure patients, *Heart* 78 (1997) 564–568.
- [4] V.E. Hagens, A.V. Ranchor, E. Van Sonderen, H.A. Bosker, O. Kamp, J.G. Tijssen, J.H. Kingma, H.J. Crijns, I.C. Van Gelder, RACE Study Group, Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the rate control versus electrical cardioversion (RACE) study, *J. Am. Coll. Cardiol.* 43 (2004) 241–247.
- [5] D.G. Jones, S.K. Haldar, W. Hussain, R. Sharma, D.P. Francis, S.L. Rahman-Haley, T.A. McDonagh, S.R. Underwood, V. Markides, T. Wong, A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure, *J. Am. Coll. Cardiol.* 61 (2013) 1894–1903.
- [6] G.C. Gronefeld, J. Lillenthal, K.H. Kuck, S.H. Hohnloser, Pharmacological Intervention in Atrial Fibrillation (PIAF) Study investigators, Impact of rate versus rhythm control on quality of life in patients with persistent atrial fibrillation. Results from a prospective randomized study, *Eur. Heart J.* 24 (2003) 1430–1436.
- [7] J. Carlsson, S. Miketic, J. Windeler, A. Cuneo, S. Haun, S. Micus, S. Walter, U. Tebbe, STAF Investigators, Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the strategies of treatment of atrial fibrillation (STAF) study, *J. Am. Coll. Cardiol.* 41 (2003) 1690–1696.
- [8] L.S. Jenkins, M. Brodsky, E. Schron, M. Chung, T. Rocco Jr., E. Lader, M. Constantine, R. Sheppard, D. Holmes, D. Mateski, L. Floden, M. Prasun, H.L. Greene, L. Shemanski, Quality of life in atrial fibrillation: the atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study, *Am. Heart J.* 149 (2005) 112–120.
- [9] H. Tsuneoka, A. Koike, O. Nagayama, K. Sakurada, J. Kato, A. Sato, T. Yamashita, K. Aonuma, Prognostic value of cardiopulmonary exercise testing in cardiac patients with atrial fibrillation, *Int. Heart J.* 53 (2012) 102–107.
- [10] N.S. Lok, C.P. Lau, Oxygen uptake kinetics and cardiopulmonary performance in lone atrial fibrillation and the effects of sotalol, *Chest* 111 (1997) 934–940.
- [11] J. Jaber, C. Cirenza, A. Amaral, J. Jaber, J.A. Oliveira Filho, A.A. de Paola, Correlation between heart rate control during exercise and exercise capacity in patients with chronic atrial fibrillation, *Clin. Cardiol.* 34 (2011) 533–536.
- [12] J. Buber, M. Glikson, M. Eldar, D. Luria, Exercise heart rate acceleration patterns during atrial fibrillation and sinus rhythm, *Ann. Noninvasive Electrocardiol.* 16 (2011) 357–364.
- [13] H. Itoh, R. Ajisaka, A. Koike, S. Makita, K. Omiya, Y. Kato, H. Adachi, M. Nagayama, T. Maeda, A. Tajima, N. Harada, K. Taniguchi, Committee on Exercise Prescription for Patients (CEPP) members, Heart rate and blood pressure response to ramp exercise and exercise capacity in relation to age, gender, and mode of exercise in a healthy population, *J. Cardiol.* 61 (2013) 71–78.
- [14] R. Zakeri, B.A. Borlaug, S.E. McNulty, S.F. Mohammed, G.D. Lewis, M.J. Semigran, A. Deswal, M. LeWinter, A.F. Hernandez, E. Braunwald, M.M. Redfield, Impact of atrial fibrillation on exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study, *Circ. Heart Fail.* 7 (2014) 123–130.
- [15] P. Agostoni, M. Emdin, U. Corra, F. Veglia, D. Magri, C.C. Tedesco, E. Berton, C. Passino, E. Bertella, F. Re, A. Mezzani, R. Belardinelli, C. Colombo, R. La Gioia, M. Vicenzi, A. Giannoni, D. Scrutinio, P. Giannuzzi, C. Tondo, A. Di Lenarda, G. Sinagra, M.F. Piepoli, M. Guazzi, Permanent atrial fibrillation affects exercise capacity in chronic heart failure patients, *Eur. Heart J.* 29 (2008) 2367–2372.
- [16] F.I. Parthenakis, A.P. Patrianakos, E.I. Skolidis, G.F. Diakakis, E.A. Zacharis, G. Chlouverakis, I.K. Karalis, P.E. Vardas, Atrial fibrillation is associated with increased neurohumoral activation and reduced exercise tolerance in patients with non-ischemic dilated cardiomyopathy, *Int. J. Cardiol.* 118 (2007) 206–214.
- [17] B. Greenberg, K. Chatterjee, W.W. Parmley, J.A. Werner, A.N. Holly, The influence of left ventricular filling pressure on atrial contribution to cardiac output, *Am. Heart J.* 98 (1979) 742–751.
- [18] M.B. Elshazly, T. Senn, Y. Wu, B. Lindsay, W. Saliba, O. Wazni, L. Cho, Impact of atrial fibrillation on exercise capacity and mortality in heart failure with preserved ejection fraction: insights from cardiopulmonary stress testing, *J. Am. Heart Assoc.* 6 (2017) <https://doi.org/10.1161/JAHA.117.006662>.
- [19] S. Wright, Z. Sasson, T. Gray, A. Chelvanathan, S. Esfandiari, J. Dimitry, S. Armstrong, S. Mak, J.M. Goodman, Left atrial phasic function interacts to support left ventricular filling during exercise in healthy athletes, *J. Appl. Physiol.* 119 (2015) 328–333.
- [20] C.M. Linde-Edelstam, A. Juhlin-Dannfelt, R. Nordlander, S.K. Pehrsson, The hemodynamic importance of atrial systole: a function of the kinetic energy of blood flow? *Pacing Clin. Electrophysiol.* 15 (1992) 1740–1749.
- [21] A. Vallebona, G. Gigli, S. Orlandi, G. Reggardo, Heart rate response to graded exercise correlates with aerobic and ventilatory capacity in patients with heart failure, *Clin. Cardiol.* 28 (2005) 25–29.

- [22] Y. Kato, S. Suzuki, T. Uejima, H. Semba, O. Nagayama, E. Hayama, T. Yamashita, The relationship between resting heart rate and peak VO<sub>2</sub>: a comparison of atrial fibrillation and sinus rhythm, *Eur. J. Prev. Cardiol.* 13 (2016) 1429–1436.
- [23] M. Matsuda, Y. Matsuda, T. Tada, T. Yamagishi, R. Kusukawa, Absence of atrial contraction and exercise in patients with isolated atrial fibrillation, *Chest* 100 (1991) 1549–1552.
- [24] H.A. Jamil, J. Gierula, M.F. Paton, R. Byrom, J.E. Lowry, R.M. Cubbon, D.A. Cairns, M.T. Kearney, K.K. Witte, Chronotropic incompetence does not limit exercise capacity in chronic heart failure, *J. Am. Coll. Cardiol.* 67 (2016) 1885–1896.
- [25] K. Ueshima, M. Nasu, I. Segawa, J. Kamata, N. Kobayashi, M. Nakamura, N. Chiba, K. Hiramori, What determines the heart rate response to exercise in patients with atrial fibrillation? *Jpn. Heart J.* 41 (2000) 445–450.
- [26] S.R. Ulimoen, S. Enger, A.H. Pripp, M. Abdelnoor, H. Arnesen, K. Gjesdal, A. Tveit, Calcium channel blockers improve exercise capacity and reduce N-terminal pro-B-type natriuretic peptide levels compared with beta-blockers in patients with permanent atrial fibrillation, *Eur. Heart J.* 35 (2014) 517–524.